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Background:  This study aims to investigate the discrepancy between clinicians’ perceptions and actual achievement rates of low 
density lipoprotein cholesterol (LDL-C) in Korean patients with diabetes according to updated American Diabetes Association 
(ADA)/American College of Cardiology Foundation (ACC) recommendations. 
Methods:  This is a multi-center, retrospective, non-interventional, observational study. Diabetic patients aged 18 years or older 
were eligible if they had been diagnosed with hypercholesterolemia or were receiving a lipid-lowering therapy between May 2010 
and August 2010. The information was obtained by reviewing medical records and using a self-completed questionnaire to exam-
ine physician perceptions. 
Results:  A total of 2,591 subjects who satisfied the inclusion criteria were enrolled. Highest-risk and high-risk patients account-
ed for 61.9% and 38.1% of the patients, respectively. Although most (96.3%) underwent a statin monotherapy or a statin-based 
combination therapy, just 47.4% of patients attained the LDL-C target. However, the physicians’ perceptions on target achieve-
ment rate (70.6%) were different from the actual results (47.4%). Many patients (65.3%) remained on the starting doses of statins, 
despite evidence of poor achievement of lipid goals. 
Conclusion:  Only less than half of patients with diabetes attained the LDL-C goal. The surveys showed that poor physician per-
formance might be due to the lack of recognition on ADA/ACC consensus causing a low LDL-C target attainment rate. There-
fore, changes in doctor perception are needed to attain target LDL-C level and reduce cardiovascular risk in Korean patients with 
diabetes.
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INTRODUCTION
Cardiovascular disease (CVD) is the major cause of mortality 
and morbidity in patients with type 2 diabetes [1]. The increased 
risk of CVD in subjects with type 2 diabetes consists of multi-
ple factors such as hypertension, smoking, albuminuria and 
hypercholesterolemia [2]. Among them, hypercholesterolemia 
is one of the key factors that are amenable to intervention. 
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  A large body of research ranging from molecular to popula-
tion studies indicates that elevated low density lipoprotein 
cholesterol (LDL-C) is a major predictor of CVD, including in 
populations with diabetes [3,4]. Treatments for lowering LDL-
C below the target level recommended by several guidelines 
are emphasized in patients with type 2 diabetes due to the in-
creased risk of CVD [5]. Patients with type 2 diabetes without 
a history of myocardial infarction are regarded to have the 
same risk of a coronary event as patients without diabetes who 
have a history of myocardial infarction [6]. This observation 
was part of the basis for the recommendation by the Adult 
Treatment Panel III (ATP III) of the National Cholesterol Edu-
cation Program (NCEP) that diabetes should be considered a 
“coronary heart disease risk equivalent” and the resulting tar-
get for aggressive reduction of risk factors [7]. In line with this, 
recent guidelines from the American Diabetes Association 
(ADA) recommended the use of statins for primary preven-
tion of CVD in type 2 diabetes patients [8]. Considering the 
results of previous study mentioned above [6], recent guide-
lines will provide good evidence on the quantitative relation 
between achieving target cholesterol concentration and the 
probability of cardiovascular events in subjects with diabetes 
[9]. 
  In 2008, the ADA, in consensus with the American College 
of Cardiology Foundation (ACC), released guidelines [10] fol-
lowing the NCEP 2003 updated recommendations which in-
cluded an “optional” LDL-C goal <70 mg/dL for patients who 
are at the “highest risk” for CVD [11]. Highest-risk patients 
were defined as 1) patients with CVD or 2) patients with dia-
betes plus one or more additional major CVD risk factors 
(smoking, hypertension, and family history of premature 
CVD). High-risk patients was defined as 1) patients who have 
diabetes but have no major cardiovascular risk factors and 2) 
patients who do not have diabetes or CVD but have more than 
two major cardiovascular risk factors. For these patients, the 
guidelines recommended a target LDL-C less than 100 mg/dL.
  Despite available therapies and increased attention to hy-
percholesterolemia, many patients failed to achieve the LDL-C 
goals [12]. Data from the third U.S. National Health and Nu-
trition Examination Survey (NHANES;1988-1994) showed 
only 42% of patients with diabetes achieved an LDL-C <130 
mg/dL [13]. More recent data with the NCEP 2004 updated 
recommendations demonstrated only 29.4% of very-high-risk 
patients with both diabetes and CVD reached the LDL-C goal 
of <70 mg/dL in the United States [14]. There is a need to bet-
ter understand the reasons why most patients failed to reach 
these goals despite pharmacological treatment.
  Unfortunately, it is uncertain whether target LDL-C level is 
commonly reached in Korean patients with diabetes. There-
fore, we aimed to investigate the lipid target attainment rates 
according to the ADA and ACC consensus recommendation 
in Korean patients with diabetes and investigate physician per-
ceptions on lipid target attainment and compared them with 
actual attainment rates. 
METHODS
Subjects
The study population consisted of 2,661 patients who were 
under the care of diabetic specialists at the 53 secondary and 
tertiary hospitals in Korea between 1 May 2010 and 31 August 
2010 (Fig. 1). Patients were selected from the outpatient clinics 
of these hospitals with the following selection criteria: 1) type 
2 diabetes according to ADA criteria, 2) at least 18 years of age, 
3) newly diagnosed with hypercholesterolemia or previously 
diagnosed with hypercholesterolemia but not on lipid-lower-
ing medication for at least one month prior to the initial visit, 
4) on lipid-lowering treatment for at least 3 months. Hyper-
cholesterolemia was defined according to NCEP-ATP III [15]. 
Patients were eligible for enrollment if they had visited the 
Patients who visited clinic between May 1 and 
Aug 31, 2010
Patients with minimum 3 months pre-
index eligibility 
(n=2,691)
Exclude patients without laboratory
results at baseline and final visit
(n=2,591)
Exclude patients missing data to calculate Framing-
ham 10-yr risk
(n=2,093)
Fig. 1. Enrollment of diabetic patients with hypercholesterol-
emia.630
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hospital at least once during the last 3 months. Detailed infor-
mation on baseline characteristics including age, sex, body 
mass index (BMI), smoking status, the duration of diabetes, 
hypertension status, past history of CVD, family history of 
premature CVD and concomitant medication use was collect-
ed by study site personnel through review of medical records. 
Hypertension was defined as a systolic blood pressure (SBP) 
≥140 mm Hg and/or diastolic BP (DBP) ≥90 mm Hg or tak-
ing antihypertensive medications. History of CVD was based 
on each subject’s history of angina, myocardial infarction and/
or cerebrovascular accidents. Smoking status was classified 
into non-smoker, ex-smoker and current smoker. The self-
completed questionnaire on physicians’ perceptions of the 
achievement rates of LDL-C targets was additively completed 
through an online survey.
  We excluded subjects who met at least one of the following 
criteria: 1) current enrollment in other clinical studies, 2) par-
ticipation in any clinical studies within the previous 90 days 
(except non-interventional and registry studies), 3) unable or 
unwilling to reveal medical records. After exclusion of ineligi-
ble subjects, 2,591 subjects (1,278 men, mean age 56.1±10.8; 
and 1,313 women, mean age 61.1±10.2) were included in this 
study. 
Study design
This study was a multi-center, non-interventional study using 
retrospective medial chart reviews. Doctors provided detailed 
information on patient characteristics and their perception of 
LDL-C treatment goal achievement. All data were entered and 
collected in an eCRF, and the eCRF manual was provided sep-
arately to the investigator. This study was approved by the In-
stitutional Review Board of the hospitals to which the partici-
pating investigators belonged.
Study variables
The values of LDL-C were determined by direct measurement 
when triglyceride (TG) was higher than 400 mg/dL or patients 
were on fibrates. Except those conditions, LDL-C was calculat-
ed from the Friedwald formula as following: Total cholesterol 
(TC)-[high density lipoprotein cholesterol (HDL-C)+TG/5]. 
These values were recorded using the web database. Laborato-
ry records included the date of testing. The Framingham risk 
score modified by ATP III, which incorporated age, gender, 
LDL-C, HDL-C, BP, smoking status and TC, was used.
  Use of lipid-lowering medication was determined by medi-
cal records. Patients were considered to be on a lipid lowering 
therapy if they had at least one subscription for any lipid-mod-
ifying medications during the follow-up period. Statin titra-
tion was defined as an increase in the strength of the dispensed 
statin. A switch was defined as a change of lipid drugs, either 
statin or non-statin. 
Study Objectives 
The objective of this study was to investigate the discrepancy 
between clinicians’ perceptions and the actual achievement of 
LDL-C targets in Korean diabetic patients according to the 
updated ADA/ACC recommendations. 
Statistical methods
Continuous variables are expressed as mean±standard devia-
tion, and categorical variables are expressed as number and 
proportions (%). Most data are summarized with descriptive 
statistics. Student’s t-tests or paired t-tests were used for con-
tinuous variables, and chi-squared tests were used for categor-
ical variables. Multivariate logistic regression analysis was per-
formed to identify the factors contributing to the failure of 
LDL-C target attainment. Significance was set at 0.05. All sta-
tistical analysis was performed using SPSS version 14.0 for 
Windows (SPSS Inc., Chicago, IL, USA). 
RESULTS 
Clinical and biochemical characteristics of the subjects
Baseline characteristics of study participants are presented in 
Table 1. The mean age of patients was 60.8±10.5 years. On av-
erage, the patients had a mean BMI of 25.2 kg/m
2. Male sub-
jects had a higher proportion of CVD and atrial fibrillation 
and were younger, more often at highest-risk, and current 
smokers (P<0.05 for each). Patients with previously diagnosed 
CVD compromised 10.8% of subjects. 
 
Attainment of target LDL-C level
According to the 2008 ADA/ACC guidelines, 1,603 (61.9%) of 
the 2,591 patients were highest-risk and 988 (38.1%) were high-
risk (Table 1). The mean observed duration of statin use was 
23.1±26.2 months. The achievement rate of target LDL-C level 
(<70 mg/dL in the highest-risk group and <100 mg/dL in the 
high-risk group, respectively) was 8.8% at baseline. After treat-
ment during the follow-up period, LDL-C target attainment 
increased up to 47.4% (Fig. 2). Among the high-risk patients 631
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(n=988), LDL-C goal attainment increased from 8.2% to 
68.6%. For the highest-risk group (n=1,603), target LDL-C at-
tainment increased from 9.2% to 34.2%. 
  Further analyses of the proportion of patients achieving the 
goal were conducted according to sex. The percentage of pa-
tients reaching the LDL-C goal was similar between female 
(46.2%) and male patients (48.5%). 
  Regarding the reduction of risk for future CVD by decreased 
LDL-C level, Framingham risk score was significantly lower 
after using lipid-lowering drug at final visit compared to the 
baseline Framingham risk score, as shown in Fig. 3 (P<0.0001). 
When we compared the scores by stratifying the subjects who 
achieved the LDL-C target into high- and highest-risk groups, 
a significant difference was observed in the both group at the 
initial visit and the final visit (8.5±3.3 vs. 6.1±3.2, P<0.0001 
in the highest risk patients; 8.4±3.2 vs. 5.9±3.2, P<0.001 in 
the high risk patients). Furthermore, goal-achievers at final 
visit had significant reduction of Framingham risk score at the 
final visit compared to non-achievers (P<0.05). 
Physician treatment strategies and factors affecting LDL-C 
goal attainment
In general, 65.3% of patients did not switch drugs between 
baseline and the final visit (Fig. 4A). Increased titration was 
prescribed in only 3.2% of patients, while 4.0% were prescribed 
decreased titration. Among 3-hydroxy-3-methyl-CoA reduc-
tase (HMG-CoA reductase) inhibitors, rosuvastatin was the 
most frequently used one (48.8%). Fibrates were being taken 
by 6.9% of patients at the initial visit and were newly subscribed 
to 3.4% of patients during the follow-up period. 
  To identify the factors affecting LDL-C goal attainment, we 
compared the baseline characteristics between target LDL-C 
achievers and non-achievers regarding to sex, age, BMI, HbA1c, 
LDL-C, HDL-C, TC, smoking history and blood pressure. The 
Table 1. Clinical and biochemical characteristics of the sub-
jects
Characteristic Total Male Female
Sex 2,591 (100.0) 1,278 (49.3) 1,313 (50.7)
Age, yr 60.8±10.5 56.1±10.8 61.1±10.2
BMI, kg/m
2 25.2±3.3 25.4±3.0 25.1±3.5
Known CVD 281 (10.8) 161 (12.6) 120 (9.1)
Family history of  
premature CVD
50 (1.9) 33 (2.6) 17 (1.3)
Atrial fibrillation 31 (1.2) 19 (4.5) 12 (0.9)
Duration of statin 
treatment, mo
23.1±26.2 23.0±25.5 23.3±26.8
Classification
a 
Highest-risk patients 1,603 (61.9) 857 (53.5) 746 (46.5)
High-risk patient 988 (38.1) 421 (42.6) 567 (57.4)
Smoking history
Non smoker 1,375 (53.1) 309 (24.2) 1,066 (81.2)
Ex-smoker 373 (14.4) 341 (26.7) 32 (2.4)
Smoker 345 (13.3) 323 (25.3) 22 (1.7)
HbA1c, % 7.81±1.80 7.80±1.84 7.82±1.77
LDL-C, mg/dL 132.7±40.2 128.2±40.6 137.6±39.1
≤70 229 (8.8) 136 (10.6) 93 (7.1)
70<~≤100 308 (11.9) 162 (12.7) 146 (11.1)
100<~<130 579 (22.3) 307 (24.0) 272 (20.7)
130≤~<160 871 (33.6) 419 (32.8) 452 (34.4)
160≤ 604 (23.3) 254 (19.9) 350 (26.7)
HDL-C, mg/dL  47.7±12.1 45.7±11.4 49.7±12.5
TC, mg/dL 218.5±44.2 214.2±44.0 222.7±43.9
TG
b, mg/dL 167 (114,232)  178 (120,250) 158 (110,215)
Blood pressure, mm Hg
SBP 129.6±14.9 130.7±14.7 128.7±14.9
DBP 79.0±10.6 80.4±10.5 77.5±10.4
Values are presented as mean±standard deviation or number (%).
BMI, body mass index; CVD, cardiovascular disease; LDL-C, low 
density lipoprotein cholesterol; HDL-C, high density lipoprotein 
cholesterol; TC, total cholesterol; TG, triglyceride; SBP, systolic blood 
pressure; DBP, diastolic blood pressure.
aClassification of CVD risk according to ADA/ACC consensus, 
bMe-
dian, interquartile values.
Fig. 2. Low density lipoprotein cholesterol target attainment 
rates according to the 2008 American Diabetes Association 
(ADA)/American College of Cardiology Foundation (ACC) 
consensus statement.
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results showed that patients who did not attain the LDL-C goal 
were more likely to be current smokers, have a family history 
of premature CVD, hypertension, lower HDL-C level, and 
higher LDL-C level (P<0.05 each). A logistic regression analy-
sis was performed with these variables, which showed that 
subjects with older patients, patients with higher baseline 
LDL-C and current smokers tended to fail to achieve target 
LDL-C level. When we analyzed the factors in high-risk and 
highest-risk group separately, age, smoking, and higher base-
line LDL-C level were the significant factors affecting LDL-C 
target attainment in the high-risk group, while age and smok-
ing history were those in the highest-risk group (P<0.05, re-
spectively). The effects of non-statins, statin titration, and 
switching between lipid-lowering drugs on goal achievement 
were not analyzed. The average treatment doses were not sta-
tistically different between groups. 
Physician perceptions of LDL-C goal achievement
To analyze the possible factors contributing to the low target 
goal attainment rate (47.4% overall, Fig. 2), physicians com-
pleted a self-reporting survey. As shown in Fig. 5, we found 
that physician perceptions of target LDL-C achievement dif-
fered from the guidelines. Of those who were initially tested 
for LDL-C after diagnosis of diabetes, a majority (83.2%) were 
classified as high-risk by the physicians, while only 14.8% were 
classified as highest-risk. After treatment, while 70.6% were 
perceived to have achieved the target LDL-C by physicians, 
only 47.4% achieved the goal according to the ADA/ACC 
guidelines.
  For the diagnosis of hypercholesterolemia, physicians con-
sidered the following lipid levels most important (in descend-
ing order): LDL-C (92.5%), TG (46.2%), HDL-C (38.7%), and 
TC (57.5%). From the survey, doctors reported that 96.2% used 
Fig. 3. Reduction Framingham risk score according to decrease of low density lipoprotein cholesterol level. 
aP<0.05 by Student’s 
t-test, 
bP<0.05 by paired t-test. 
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guidelines for setting target cholesterol level. The guidelines 
commonly used are shown in Fig. 6, with the NCEP ATP III 
guidelines being the most frequent.
  Ninety-eight percent of physicians reported that they in-
formed patients of their cholesterol value, and most (86.8%) 
also informed patients of their LDL-C level. Regular follow-
ups on cholesterol level were completed every 6 months in 
56.6% of cases, every 3 months in 25.5%, and once a year in 
13.2%. When the target goal was not achieved, physicians re-
plied that they would increase dosage (78.3%) or change med-
ication (64.2%) (Fig. 4B). However, increased titration was 
carried out in only 3.2% of patients (Fig. 4A).
DISCUSSION
In this study, the ADA/ACC recommended LDL-C goal was 
achieved in approximately 47.4% of Korean patients with dia-
betes, which was significantly lower than physicians’ percep-
tions (70.6%). Compared to those who did not reach the target 
LDL-C level, the risk of future coronary heart disease (CHD) 
was substantially lower among those who did achieve the goal, 
as shown in the reduction of the Framingham risk score. 
  This study also demonstrated that there was a large gap be-
tween physicians’ perceptions and guidelines in categorizing 
the severity of hypercholesterolemia. Although most physi-
cians answered that they would increase the dosage of lipid-
lowering medications if the target LDL-C goal was not reached, 
only 3.2% prescribed increased titration (Fig. 4A). Although 
factors affecting physicians’ recognition were not analyzed, in-
ferring by the fact that most patients were considered high-
risk but not highest-risk to physicians, the updated guidelines 
might not be fully recognized. 
  During the treatment period, 65.3% of patients did not have 
any drug adjustment, including up-titration, add-on, or drug 
switching (Fig. 4A). Factors such as old age, multi-drug usage, 
and adverse effects of up-titration or combination therapy 
might have affected physician decisions. Also, the guidelines 
used by the physicians may have affected LDL-C level. From 
the survey, NCEP APT III guidelines [7] (59.8%) were the most 
frequently used. The 2009/2010 ADA guidelines [8] (27.5%), 
ADA/ACC consensus statement (4.9%), and Korean Diabetes 
Association (KDA) guidelines [16] (5.9%) were applied less 
frequently.
  A few studies have evaluated the attainability of the more 
aggressive LDL-C treatment goal recommended by the NCEP 
ATPIII or ADA guidelines [14,17]. Kennedy et al. [14] report-
ed that it would be extremely difficult to reach an LDL-C goal 
of <70 mg/dL in patients with diabetes and CVD in the Unit-
ed States. They estimated that 25% of patients would require 
more than two lipid-lowering drugs at maximal doses to attain 
this goal [14]. In a recent survey of 4,888 patients treated with 
statins, only 38% reached the recommended LDL-C level ac-
cording to the NCEP guidelines [12]. Although our study was 
conducted ten years later and used the ADA/ACC guidelines, 
our findings were consistent with the results of above studies. 
  It has been suggested that if LDL-C goals are not met, it is 
Fig. 5. The discrepancy between physicians’ perception of low 
density lipoprotein cholesterol (LDL-C) goal attainment and 
actual results according to the 2008 American Diabetes Asso-
ciation (ADA)/American College of Cardiology Foundation 
(ACC) guidelines.
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necessary to take patient opinions about their illness into ac-
count. A prospective survey in Australia using prescription re-
newals as a surrogate for drug discontinuation found that 60% 
of patients stopped their medication after 1 year, and half of 
them discontinued within 3 months of therapy initiation. A 
major reason for discontinuation was lack of self-perception 
regarding the need for further treatment [18]. However, when 
patients were compliant, there were many possible pitfalls un-
derlying patient non-achievement with current treatment goals 
such as inappropriate drug or dose selection, limited drug effi-
cacy. Failure to achieve target LDL-C level was in large part 
due to inadequate doses or titration by physicians. Most pa-
tients who began treatment with a statin remained at the ini-
tial dose [19,20]. 
  In other studies [19,21], patients with diabetes had the low-
est success rate in the treatment with lipid lowering drugs. 
However, subjects with diabetes are known to be at a substan-
tially higher risk for stroke [22], CHD, and death [5]. More-
over, diabetics with [23] or without [24] established CHD 
benefit from statin treatment in a manner equal to or greater 
than that of nondiabetic subjects [20,21]. A subgroup analysis 
of the Greek Atorvastatin and Coronary Heart Disease Evalu-
ation (GREACE) study which compared structured care and 
usual care in clinical practice in Greece [23] found that diabet-
ic patients showed early reductions of more than 50% in total 
mortality, coronary mortality, coronary morbidity, and stroke 
in the structured care arm. The Collaborative Atorvastatin Di-
abetes Study (CARDS) showed that, over a 3-year period, a 
daily 10 mg dose of atorvastatin reduced the risk of a major 
cardiovascular event in patients with type 2 diabetes mellitus 
without incident CHD by 37% and that of stroke by almost 
half (48%) [24]. In our study population, 10.8% of subjects had 
previous CVD, and a majority (61.9%) was classified as at high-
est-risk. Although the current treatment gap in LDL-C targets 
is comparable with published international data, this gap is 
unacceptable, and undoubtedly leads to an excess number of 
cardiovascular deaths, infarcts, strokes and need for revascu-
larization. To improve the management of hypercholesterol-
emia, physicians should be aware of and focus on patients with 
diabetes. A recent randomized controlled trial demonstrated 
the incremental impact of team-based care approach to cho-
lesterol management in patients with diabetes [25]. Although 
primary study outcome was set as achieving LDL-C level of 
100 mg/dL regardless of CVD risk, it showed that physician-
paramedical staff approach can be considered to improve LDL-
C goal attainment.
  A major strength of this study was the large sample size; 
nearly 2,600 patients were included in the main analysis. An-
other advantage is the inclusion of a survey concerning physi-
cian perceptions in the diagnosis of hypercholesteroelemia 
and treatment strategy. However, this study had several limita-
tions. The diagnosis of CVD used to classify patients into high-
risk and highest-risk categories was based on a chart review. 
Thus, misclassification of LDL-C severity and outcome may 
have occurred. Also, we did not have detailed dietary informa-
tion for the patients and therefore could not estimate the ef-
fects of dietary intervention on LDL-C level [26]. Another 
limitation was that the study population did not reflect pa-
tients with diabetes who were receiving primary care. Finally, 
the sex-specific Framingham CHD predictions have not been 
validated in Koreans. The Framingham prediction was first 
demonstrated in Caucasians and was later applied to Japanese-
Americans and other ethnic groups after recalibration for dif-
fering prevalence of risk factors [27]. However, no validation 
or recalibration has been carried out in Koreans. Furthermore, 
our study was able to measure the effect of statins over only a 
short-term period. In many instances, statin treatment had 
been ongoing for a long period of time. Additionally, patient 
compliance with the lipid-modifying drugs was not monitored. 
  In conclusion, this study showed that actual LDL-C target 
attainment rates according to the ADA/ACC consensus state-
ment were low in Korean patients with diabetes. However, 
more than 70% of physicians perceived their patients to have 
achieved these goals. Thus, our results suggested that changes 
in clinical practices and physician perceptions might be need-
ed to reach cholesterol target goals recommended by updated 
guidelines.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.
ACKNOWLEDGMENTS
This study was funded by AstraZeneca Korea.
REFERENCES
1. Bloomgarden ZT. Diabetes and cardiovascular disease. Diabe-635
Hypercholesterolemia in Korean diabetic patients
Diabetes Metab J 2011;35:628-636 http://e-dmj.org
tes Care 2011;34:e24-30.
2. Webb DR, Khunti K, Gray LJ, Srinivasan BT, Farooqi A, Ware-
ham N, Griffin SC, Davies MJ; for the ADDITION-Leicester 
study group. Intensive multifactorial intervention improves 
modelled 5-year coronary heart disease risk in screen-detected 
type 2 diabetes mellitus: a cluster randomized controlled trial. 
Diabet Med. Epub 2011 Sep 13. DOI: 10.1111/j.1464-5491. 
2011.03441.x. 
3. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, 
Faergeman G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson 
AG, Wedel H; Scandinavian Simvastatin Survival Study Group. 
Randomised trial of cholesterol lowering in 4444 patients with 
coronary heart disease: the Scandinavian Simvastatin Survival 
Study (4S). 1994. Atheroscler Suppl 2004;5:81-7.
4. Sato H, Kinjo K, Ito H, Hirayama A, Nanto S, Fukunami M, 
Nishino M, Lim YJ, Kijima Y, Koretsune Y, Nakatani D, Mizu-
no H, Shimizu M, Hori M; Osaka Acute Coronary Insufficien-
cy Study (OACIS)-LIPID Study Investigators. Effect of early 
use of low-dose pravastatin on major adverse cardiac events in 
patients with acute myocardial infarction: the OACIS-LIPID 
Study. Circ J 2008;72:17-22.
5. Almdal T, Scharling H, Jensen JS, Vestergaard H. The indepen-
dent effect of type 2 diabetes mellitus on ischemic heart disease, 
stroke, and death: a population-based study of 13,000 men and 
women with 20 years of follow-up. Arch Intern Med 2004;164: 
1422-6.
6. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabe-
tes a coronary risk equivalent? Systematic review and meta-
analysis. Diabet Med 2009;26:142-8.
7. Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults. Executive summary of the Third 
Report of the National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 
2001;285:2486-97.
8. American Diabetes Association. Standards of medical care in 
diabetes--2011. Diabetes Care 2011;34 Suppl 1:S11-61.
9. LaRosa JC. At the heart of the statin benefit. J Am Coll Cardiol 
2005;46:1863.
10. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard 
BV, Stein JH, Witztum JL; American Diabetes Association; 
American College of Cardiology Foundation. Lipoprotein 
management in patients with cardiometabolic risk: consensus 
statement from the American Diabetes Association and the 
American College of Cardiology Foundation. Diabetes Care 
2008;31:811-22.
11. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, 
Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Na-
tional Heart, Lung, and Blood Institute; American College of 
Cardiology Foundation; American Heart Association. Impli-
cations of recent clinical trials for the National Cholesterol Ed-
ucation Program Adult Treatment Panel III guidelines. Circu-
lation 2004;110:227-39.
12. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment 
assessment project (L-TAP): a multicenter survey to evaluate 
the percentages of dyslipidemic patients receiving lipid-lower-
ing therapy and achieving low-density lipoprotein cholesterol 
goals. Arch Intern Med 2000;160:459-67.
13. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thomp-
son TJ, Narayan KM. A diabetes report card for the United 
States: quality of care in the 1990s. Ann Intern Med 2002;136: 
565-74.
14. Kennedy AG, MacLean CD, Littenberg B, Ades PA, Pinckney 
RG. The challenge of achieving national cholesterol goals in 
patients with diabetes. Diabetes Care 2005;28:1029-34.
15. National Cholesterol Education Program (NCEP) Expert Pan-
el on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III). Third Re-
port of the National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III) final 
report. Circulation 2002;106:3143-421.
16. Ko SH, Kim SR, Kim DJ, Oh SJ, Lee HJ, Shim KH, Woo MH, 
Kim JY, Kim NH, Kim JT, Kim CH, Kim HJ, Jeong IK, Hong 
EK, Cho JH, Mok JO, Yoon KH; Committee of Clinical Prac-
tice Guidelines, Korean Diabetes Association. 2011 clinical 
practice guidelines for type 2 diabetes in Korea. Diabetes Metab 
J 2011;35:431-6.
17. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, 
Tsang JL, Jaffer S, Kates ML, Leiter LA, Fitchett DH, Langer A, 
Goodman SG; Vascular Protection (VP) and Guidelines Ori-
ented Approach to Lipid Lowering (GOALL) Registries Inves-
tigators. Contemporary management of dyslipidemia in high-
risk patients: targets still not met. Am J Med 2006;119:676-83.
18. Simons LA, Levis G, Simons J. Apparent discontinuation rates 
in patients prescribed lipid-lowering drugs. Med J Aust 1996; 
164:208-11.
19. Diamantopoulos EJ, Athyros VG, Yfanti GK, Migdalis EN, 
Elisaf M, Vardas PE, Manolis AS, Karamitsos DT, Ganotakis 
ES, Hatseras D; OLYMPIC Study Group. The control of dyslip-636
Hwang JY, et al.
Diabetes Metab J 2011;35:628-636 http://e-dmj.org
idemia in outpatient clinics in Greece (OLYMPIC) Study. An-
giology 2005;56:731-41.
20. Hobbs FD, Southworth H. Achievement of English National 
Service Framework lipid-lowering goals: pooled data from re-
cent comparative treatment trials of statins at starting doses. 
Int J Clin Pract 2005;59:1171-7.
21. Alzahrani T, Marrat S, Haider A. Management of dyslipidemia 
in primary care. Can J Cardiol 2003;19:1499-502.
22. Tuomilehto J, Rastenyte D, Jousilahti P, Sarti C, Vartiainen E. 
Diabetes mellitus as a risk factor for death from stroke. Pro-
spective study of the middle-aged Finnish population. Stroke 
1996;27:210-5.
23. Athyros VG, Papageorgiou AA, Symeonidis AN, Didangelos 
TP, Pehlivanidis AN, Bouloukos VI, Mikhailidis DP; GREACE 
Study Collaborative Group. Early benefit from structured care 
with atorvastatin in patients with coronary heart disease and 
diabetes mellitus. Angiology 2003;54:679-90.
24. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, 
Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charl-
ton-Menys V, Fuller JH; CARDS investigators. Primary pre-
vention of cardiovascular disease with atorvastatin in type 2 
diabetes in the Collaborative Atorvastatin Diabetes Study 
(CARDS): multicentre randomised placebo-controlled trial. 
Lancet 2004;364:685-96.
25. Pape GA, Hunt JS, Butler KL, Siemienczuk J, LeBlanc BH, Gil-
landers W, Rozenfeld Y, Bonin K. Team-based care approach 
to cholesterol management in diabetes mellitus: two-year clus-
ter randomized controlled trial. Arch Intern Med 2011;171: 
1480-6.
26. Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, 
Kris-Etherton PM. Effects of the National Cholesterol Educa-
tion Program’s Step I and Step II dietary intervention programs 
on cardiovascular disease risk factors: a meta-analysis. Am J 
Clin Nutr 1999;69:632-46.
27. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD 
Risk Prediction Group. Validation of the Framingham coro-
nary heart disease prediction scores: results of a multiple eth-
nic groups investigation. JAMA 2001;286:180-7.